中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2177 records (took 0.037 seconds)

    PROGRAM GENERATION APPARATUS AND PROGRAM GENERATION METHOD
    51.
    发明公开
    PROGRAM GENERATION APPARATUS AND PROGRAM GENERATION METHOD 审中-公开

    公开(公告)号：US20240168447A1

    公开(公告)日：2024-05-23

    申请号：US18280673

    申请日：2021-04-02

    Applicant: Mitsubishi Electric Corporation ,  OSAKA UNIVERSITY

    Inventor： Kohei FUJITA ,  Toshimitsu USHIO

    IPC: G05B19/042 ,  G05B19/05 ,  G05B19/408

    CPC classification number: G05B19/0426 ,  G05B19/056 ,  G05B19/408

    Abstract: Operating efficiency of a target to be controlled is enhanced, and a degree of freedom in converting a language of a program is enhanced. A program generation apparatus includes: a design information conversion unit that converts design information, which includes a plurality of states of a device, relationships between signals and the states of the device, and time required for changes of the states of the device, into a model, which includes a state set, an input set, a transition function, and time required for transitions; a control law derivation unit that derives a control law, based on a requirements specification including a specification related to the time required for the transitions and the model, so as to satisfy the requirements specification; and a program generation unit that generates a program, based on the control law.

    BILE DUCT CHIP AND USE THEREOF
    54.
    发明公开
    BILE DUCT CHIP AND USE THEREOF 审中-公开

    公开(公告)号：US20240150691A1

    公开(公告)日：2024-05-09

    申请号：US18280659

    申请日：2022-03-09

    Applicant: Kyoto University ,  OSAKA UNIVERSITY

    Inventor： Kazuo TAKAYAMA ,  Yusuke TORISAWA ,  Kenji OSAFUNE ,  Maki KOTAKA ,  Sayaka DEGUCHI ,  Hiroyuki MIZUGUCHI

    IPC: C12M3/00 ,  C12M1/00 ,  C12M3/06

    CPC classification number: C12M21/08 ,  C12M23/16 ,  C12M29/04

    Abstract: There is provided a bile duct chip that is a bile duct chip (200) including a membrane (210) through which substances are movable from one surface to the other surface, a first substrate (221) having a recessed part that forms a first flow path (220), and a second substrate (231) having a recessed part that forms a second flow path (230), in which the first substrate (221), the membrane (210), the second substrate (231) are stacked in this order, the recessed part of the first substrate (221) has an opening portion facing the one surface of the membrane (210), the recessed part of the second substrate has an opening portion facing the other surface of the membrane (210), the one surface of the membrane (210) forms a part of the first flow path (220), the other surface of the membrane (210) forms a part of the second flow path (230), the first flow path (220) and the second flow path (230) communicate with each other through the membrane (210), and bile duct epithelial cells (222) are disposed on a surface of an inner wall of the first flow path (220) to form a tube.

    Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
    56.
    发明授权
    Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure 有权

    公开(公告)号：US11969459B2

    公开(公告)日：2024-04-30

    申请号：US16477878

    申请日：2018-01-26

    Applicant: StemRIM Inc. ,  OSAKA UNIVERSITY

    Inventor： Katsuto Tamai ,  Yoshiki Sawa ,  Shigeru Miyagawa ,  Takashi Kido ,  Takasumi Goto ,  Takehiko Yamazaki

    IPC: A61K38/00 ,  A61K38/19 ,  A61P9/10 ,  C07K14/00

    CPC classification number: A61K38/19 ,  A61P9/10

    Abstract: The present inventors have found that HMGB1 fragment peptides having a particular amino acid sequence exhibit the effects of improvement of cardiac function, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of dilated cardiomyopathy, that the particular HMGB1 fragment peptides also exhibit the effects of improvement of cardiac function, inhibition of cardiomegaly, inhibition of cardiomyocyte hypertrophy, inhibition of myocardial fibrosis, and promotion of angiogenesis in an animal model of ischemic cardiomyopathy caused by old myocardial infarction, and that the particular HMGB1 fragment peptides exhibit the effects of inhibition of cardiomyocyte hypertrophy and inhibition of myocardial fibrosis in an animal model of hypertensive cardiomyopathy. Based on these findings, pharmaceutical compositions are provided for the prevention and/or treatment of cardiomyopathy and old myocardial infarction and chronic heart failure resulting therefrom, which comprise an HMGB1 fragment peptide having a particular amino acid sequence.

    SPECTROMETRY DEVICE AND SPECTROMETRY METHOD
    59.
    发明公开
    SPECTROMETRY DEVICE AND SPECTROMETRY METHOD 审中-公开

    公开(公告)号：US20240110830A1

    公开(公告)日：2024-04-04

    申请号：US18275245

    申请日：2021-12-20

    Applicant: Osaka University

    Inventor： Katsumasa FUJITA ,  Kazuki BANDO

    IPC: G01J3/02 ,  G01J3/04 ,  G01J3/28

    CPC classification number: G01J3/0216 ,  G01J3/0208 ,  G01J3/0224 ,  G01J3/04 ,  G01J3/2823 ,  G01J2003/045

    Abstract: A spectrometry apparatus (1) according to an embodiment includes a detection object lens that signal light from a sample S enters, a slit (41) through which the signal light passes, a wavelength dispersive element that disperses the signal light having passed the slit (41) in accordance with a wavelength, an optical detector (50) that detects the signal light that has been subjected to wavelength dispersion in the wavelength dispersive element, scanning means for scanning a detection region of the optical detector (50) in the sample, a processing unit (51) that generates a spectral image, based on a detection signal of the optical detector (50), and an illumination optical system (10) that illuminates the sample from a side of the detection object lens.

Patent Agency Ranking